Citations

Clear

4510 citation(s) found for "Scott, L".

Virtual AI-informed immunocyte profiling (VAIP) from H&E as a predictor of multi-cancer prognosis.
Jana, Mayukhmala , Aggarwal, Arpit, Shanbhogue, Nikhil, Pathak, Tilak, Toro, Paula , Lewis, James S., Wasman, Jay, Teknos, Theodoros N., Pan, Quintin, Shi, Qiuying , Schmitt, Nicole Cherie, Saba, Nabil F., Oršulić, Sandra , Bazzaro, Martina , Corredor, Germán, Madabhushi, Anant, Aggarwal, Arpit , Badve, Sunil , Thorat, Mangesh A. , Lewis, James S. , Pan, Quintin , Schmitt, Nicole C. , Steward-Tharp, Scott Michael , Saba, Nabil F. , Corredor, Germán

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 3118-3118

10.1200/jco.2026.44.16_suppl.3118 Get It

3118 Background: Improved risk stratification is critically needed across multiple cancers to guide treatment decisions. This includes reducing overtreatment in Ductal Carcinoma in Situ (DCIS), addressing late recurrence risk in estrogen receptor-positive/lymph node-negative (ER+/LN-) breast cancer (BC), and refining prognosis in head & neck squamous cell carcinomas (HNSCC), and high-grade serous ovarian carcinoma (HGSOC). Tumor-infiltrating lymphocytes (TILs) reflect anti-tumor immunity, whereas tumor-associated macrophages (TAMs) polarize toward anti-tumor M1-like (CD68+) or immunosuppressive M2-like (CD163+) phenotypes. Integrating TILs with TAM polarization markers may better capture inflammatory balance and improve outcome prediction. We developed a hematoxylin and eosin (H&E)-only AI method (VAIP) to quantify TILs and virtual CD68/CD163 TAMs to develop multi-cancer based potential prognostic models. Methods: TILs were detected on H&E with HoVer-UNet, and virtual CD68 and CD163 macrophages were inferred with VISTA. In cancer regions, we computed cell densities and immune-balance ratios and trained cancer-specific Cox models with compact feature sets (DCIS 6; HGSOC 7; ER+ 4; HNSCC 4). Prognostic stratification used disease-free survival (DFS) for DCIS (N=273), HGSOC (training N=165, independent test N=220), and ER+ BC (training N=144, test N=622), and overall survival (OS) for HNSCC (N=77), reflecting clinical endpoints. Evaluation used cross-validation for cohorts without an external test set (DCIS, HNSCC) and independent training and testing when independent cohort was available (HGSOC, ER+). Results: Risk stratification performance across cancer types is in Table 1. The DCIS model used 6 features, largely TIL-macrophage contrast ratios (TIL/M2, TIL/M1). HGSOC used 7 features with a similar ratio-heavy immune-balance signature, plus macrophage-normalized density and polarization metrics (e.g., M1/N, M/N). In contrast, ER+ BC and HNSCC achieved best performance with 4 features dominated by macrophage measures, particularly M2 density and the M1/M2 ratio. Across sites, CD163-related macrophage metrics and immune-balance ratios were consistently informative. Conclusions: Integrating H&E-visible TILs with virtual CD68/CD163 TAMs enables fully automated, H&E-only prognostic biomarkers that stratify OS and DFS across multiple cancers, demonstrating consistent prognostic value in DCIS, ER+ BC, HGSOC, and HNSCC. These findings support further study of this histomorphometric risk classifier through broader external and prospective validation. Performance across cancer types. Cancer Type Cohort C-index HR [95% CI] p-value DCIS All 0.616 1.76 [1.20-2.59] <0.001 DCIS RT/No-treatment 0.624 1.94 [1.15-3.26] 0.003 HGSOC Test 0.553 1.38 [1.02-1.87] 0.030 ER+ BC Test 0.577 1.51 [1.00-2.28] 0.004 HNSCC All 0.603 1.92 [1.03-3.36] 0.012
Prognostic value of circulating tumor DNA (ctDNA) for recurrence detection across solid tumors: A real-world meta-analysis.
Kopetz, Scott, Laliotis, George, Abdelrahim, Maen, Malla, Midhun, Martin, Robert C. G., Basu, Arnab, Bardia, Aditya, Jacobsen, Luke D., Sharma, Shruti, Toboni, Michael, Schwartz, Gary, Eroglu, Zeynep, Klempner, Samuel J., Lipsyc-Sharf, Marla, Jurdi, Adham A., Liu, Minetta C., Aleshin, Alexey, Galsky, Matthew D., Kopetz, Scott , Laliotis, George, Malla, Midhun , Kim, Richard D. , Martin, Robert C.G. , Bardia, Aditya , Sharma, Shruti , Toboni, Michael Driscoll , Schwartz, Gary , Eroglu, Zeynep , Botta, Gregory P. , Lipsyc-Sharf, Marla , Jurdi, Adham Adel , Liu, Minetta C. , Aleshin, Alexey , Galsky, Matthew D.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 11177-11177

10.1200/jco.2026.44.16_suppl.11177 Get It

11177 Background: Early detection of recurrence after curative-intent treatment is a critical priority, traditional imaging often detects relapse when disease burden is high, potentially limiting treatment efficacy. ctDNA has emerged as an established prognostic biomarker for molecular residual disease (MRD) detection and early relapse. We performed a real-world meta-analysis on published datasets that utilized personalized, tumor-informed ctDNA testing to assess its performance across tumor types and clinical management approaches. Methods: Real-world studies published from December 2022 to December 2025 using the personalized, tumor-informed Signatera ctDNA assay (Natera, Inc.) were included. Eligibility required ctDNA assessment in the MRD (2–16 weeks post-surgery (histology dependent)/pre adjuvant therapy (ACT)) and/or surveillance (post-ACT/end of the MRD window if no ACT was given) settings, with outcomes stratified by ctDNA status and hazard ratios (HR) reported from univariable or time-dependent Cox regression analysis. Exclusions included: clinical trials, biobanks, metastatic disease treated with palliative intent, case reports, reviews, editorials, or commentaries. Clinical outcomes were harmonized into a composite event-free survival (EFS) endpoint (time to recurrence, progression, or death). Pooled HRs and 95% CIs were estimated using random and fixed effects models and heterogeneity between studies was assessed using the I 2 and Cochran’s Q test. Median lead time from ctDNA-positivity to radiographic or clinical recurrence was summarized when available. Results: We identified 18 eligible publications comprising 3,004 unique patients across 15 solid tumor types. During the MRD window, ctDNA positivity was associated with a significantly increased risk of an EFS event compared with ctDNA negativity (pooled HR: 8.15; 95% CI: 6.12–10.85, I 2 = 0.00%, P = 0.844, n = 13). During the surveillance window, inclusive of post-definitive treatment, ctDNA positivity conferred an even greater EFS risk (pooled HR: 18.30; 95% CI: 14.17–23.65, I 2 = 0%, P = 0.911 for heterogeneity, n = 16). Across studies, ctDNA detection during surveillance preceded radiographic or clinical recurrence by a median of 3.20 months (95% CI: 2.50-4.10, P < 0.0001, n = 10), although this varied substantially by study/tumor type (I 2 = 80.9%). Conclusions: In this pan-cancer real-world meta-analysis, ctDNA positivity assessed using a tumor-informed assay was highly prognostic following curative-intent therapy at all timepoints evaluated with low heterogeneity between studies. These findings support the broad clinical utility of tumor-informed ctDNA testing for post-treatment risk stratification and longitudinal disease monitoring across solid tumors.
Real-world evaluation of germline pathogenic variants (PVs) in cancer-predisposition genes among unselected South Asian women with breast or ovarian cancer.
Shilpakar, Ramila , Karki, Aditi, Mina, Syeda A. , Yeakub, Nadia, Acharya, Bibek , Acharya, Sandhya Chapagain , Naseer, Hafsa, Khatun, Nazrina , Akhtar, Parveen , Mukhopadhyay, Asima , Pruthi, Sandhya, Goetz, Matthew P., Couch, Fergus J., Aziz, Zeba , Yadav, Siddhartha , Pramanik, Raja , Kataria, Babita , Pruthi, Sandhya , Bakkum‐Gamez, Jamie N. , Goetz, Matthew P. , Kaufmann, Scott H. , Couch, Fergus J. , Islam, Muhammad Rafiqul

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 10513-10513

10.1200/jco.2026.44.16_suppl.10513 Get It

10513 Background: Prior reports of high frequency of BRCA1 and BRCA2 ( BRCA1/2 ) PVs among South Asian women from Bangladesh, India, Nepal, and Pakistan with breast or ovarian cancer require validation in large prospective unselected cohorts. Methods: Individual-level anonymized patient data from two prospective cohorts were pooled to evaluate the prevalence of germline PVs among South Asian women: the South Asian Regional Alliance for Hereditary Cancers (SARAH Consortium) in Bangladesh, Nepal, and Pakistan, and the previously reported Nurse-led Genetic Counseling and Awareness (NuGenA) expansion cohort in India. Both studies enrolled consecutive cases of histologically confirmed newly diagnosed breast or epithelial ovarian cancer irrespective of age at diagnosis or family history. In both studies, participants completed questionnaires on personal and family history (first-, second- or third-degree) and provided blood for germline genetic testing after written consent. PVs in cancer predisposition genes including ATM, BARD1, BRCA1, BRCA2, BRIP1, CHEK2, MLH1, MSH2, MSH6, PALB2, RAD51C, RAD51D, and TP53 were identified as part of the studies utilizing a multigene panel and the results were returned to ordering clinicians. The data cutoff date for this analysis was November 30, 2025. Results: The analysis included 1,711 South Asian women with breast (n=1,210) or ovarian (n=501) cancer. A family history of breast or ovarian cancer was noted in 177 (10.3%). Among breast cancers, 94% were invasive, 84% were ductal, 35% were triple-negative and over two-thirds presented with nodal involvement. Germline PVs across 13 predisposition genes were observed in 17.7% of breast and 35.9% of ovarian cancers. Notably, BRCA1/2 PVs accounted for most of these PV (13.6% of breast and 28.3% of ovarian cancer cases) with PVs in all genes except BRCA1/2 under 1%. The frequency of BRCA1/2 PVs was 24.4% in triple-negative breast cancer and 8.0% in ER+/HER2-. BRCA1/2 PV carriers were diagnosed with breast cancer at a younger age than non-carriers (Median age: 42 vs 46 years, P<0.001), with no age difference observed in ovarian cancer (50 vs. 51 years, P=0.79). Notably, among the 306 BRCA1/2 PV carriers identified, 229 (74.2%) did not report a family history of breast or ovarian cancer. Conclusions: We confirm a high prevalence of BRCA1/2 PVs among unselected South Asian women with either breast or ovarian cancer. The observations of younger age at cancer diagnosis, and low rates of family history support the need for population-specific germline genetic testing and risk management strategies in South Asia.
Decompression with or without Duraplasty for Chiari I and Syringomyelia
Limbrick, David D. , Shannon, Chevis N., Bayman, Emine O., Meehan, Thanda, Kallem, Marisa, Ackerman, Laurie L. , Adelson, P. David , Albert, Gregory, Aldana, Philipp R. , Alden, Tord D. , Anderson, Richard C. E. , Baird, Lissa C., Bauer, David, Bethel-Anderson, Tammy, Bierbrauer, Karin, Brockmeyer, Douglas L. , Chern, Joshua J. , Couture, Daniel, Daniels, David J., Dauser, Robert C., Durham, Susan, Ellenbogen, Richard G., Eskandari, Ramin, Gannon, Stephen R., Grant, Gerald A., Greene, Stephanie, Gross, Naina L. , Guillaume, Daniel J. (Daniel James), Hankinson, T., Heuer, Gregory, Iantosca, Mark, Iskandar, Bermans J. , Jackson, Eric M., Keating, Robert F., Kelly, Michael P., Kennedy, Elaine, Krieger, Mark D., Kulkarni, Abhaya V., Labuda, Rick, Leonard, Jeffrey R., Maher, Cormac O. , Mangano, Francesco T. , McComb, J. Gordon, McEvoy, Sean D., Niazi, Toba N., Oakes, Jerry, Olavarria, Greg, O’Neill, Brent R., Poppe, Dorothy, Ragheb, John, Reynolds, Lisa, Selden, Nathan R., Shah, Manish N., Smyth, Matthew D., Spears, Sandy, Stone, Scellig , Strahle, Jennifer M., Tamber, M, Tramelli, Gina, Tuite, Gerald F. , Vance, Haley, Wait, Scott D. , Wellons, John C. , Whitehead, WE, Yahanda, Alexander T., Yan, Yan, Dacey, Ralph G. , Park, Tae Sung, Torner, James C., Kelly, Michael P. , Torner, James C. , Dlouhy, Brian J , Iskandar, Bermans J , Yahanda, Alexander T , Kelly, Michael P , Limbrick, David D. , Bayman, Emine O. , Ahmed, Raheel , Albert, Gregory W. , Bierbrauer, Karin S. , Daniels, David J. , Ellenbogen, Richard G., Graupman, Patrick C. , Greenberg, Jacob K , Greenfield, Jeffrey P. , Guillaume, Daniel, Iantosca, Mark, Jackson, Eric M., Jallo, George I. , Johnston, James M. , Keating, Robert F., Kennedy, Elaine, Kulkarni, Abhaya V. , McComb, J. Gordon , McKinstry, Robert C. , Menezes, Arnold H. , Poppe, Dorothy , Ragheb, John , Reeves, Samuel, Reynolds, Lisa, Selden, Nathan R. W. , Shah, Manish N. , Shimony, Joshua S. , Strahle, Jennifer M. , Tamber, Mandeep S. , Tyler‐Kabara, Elizabeth C. , Vance, E. Haley, Yahanda, Alexander T. , Park, Tae Sung

Mayo Clinic

New England Journal of Medicine | May 27, 2026 | Volume: 394 | Issue: 20 | Pages: 2015-2025

10.1056/nejmoa2402821 | PMID 42202320 Get It

State Policy Variation and Telehealth Use by Oncology Specialists Treating Medicaid Patients
Vichare, Anushree , Luo, Qian (Eric), Khera, Nandita , Gandhi, Arpita, Shipman, Scott A., Erikson, Clese, Vichare, Anushree M. , Bodas, Mandar , Luo, Qian , Erikson, Clese

Mayo Clinic

Telemedicine and e-Health | May 27, 2026 | Volume: 32 | Issue: 9 | Pages: 970-974

10.1177/15305627261455444 | PMID 42202051 Get It

Telehealth may improve access to specialized oncology care for Medicaid beneficiaries with hematological malignancies who face geographic and financial barriers. During the COVID-19 public health emergency, telehealth use expanded rapidly, yet state policies governing telehealth coverage/payment parity varied. Evidence is limited on how these policy differences influenced oncology telehealth use for Medicaid patients. We conducted a cross-sectional analysis of 2020–2021 multistate Medicaid claims. Adult and pediatric oncology specialists were identified based on board certification data. Telehealth video visits were measured monthly at the extensive margin, defined as the proportion of specialists providing any telehealth, and the intensive margin, defined as average monthly telehealth visits among telehealth providing specialists. States were categorized by private insurance telehealth policy environment: coverage and payment parity, coverage parity only, or no or unspecified parity. Telehealth use increased sharply across all states in early 2020, rising from less than 1% of specialists before the pandemic to peak levels by April 2020. Specialists practicing in coverage and payment parity states demonstrated higher and more sustained telehealth use through 2021 compared with those in coverage only or no parity states. By December 2021, 15.1% of adult specialists in coverage and payment parity states provided telehealth, compared with 8.1% in coverage-only states and 7.8% in no-parity states. Pediatric specialists showed similar patterns, though overall telehealth use remained lower. Specialists in parity states also maintained higher monthly telehealth visit volumes over time. State-level coverage and payment parity policies may have been associated with greater and sustained telehealth provision by oncology specialists treating Medicaid beneficiaries with hematologic malignancies. Maintaining supportive telehealth policies may be essential for promoting equitable access to specialized cancer care and reducing disparities among underserved populations. These findings inform future telehealth policy decisions nationally statewide.
Lipoprotein(a) and Risk of Treated Ventricular Arrhythmias in Heart Failure
Ibrahim, Ramzi, Dreher, Luke, Habib, E., Pham, Hoang Nhat, Ibrahim, Sammudeen , Bhakta, Mayurkumar, Sorajja, Dan , Shen, Win-Kuang, Scott, Luis R., Ayoub, C A, Arsanjani, R A, Masry, Hicham Z. El, Masry, Hicham El , Nabi, Hussein Abdul , Farina, Juan María, Tan, Min Choon , Noureldine, Hussein A , El Masry, Hicham Z, El Masry, Hicham , Ibrahim, Ramzi , Dreher, Luke , Farina, Juan M. , Pham, Hoang Nhat , Bhakta, Mayurkumar D. , Lee, Kwan , Scott, Luis R. , Arsanjani, Reza

Mayo Clinic

JAMA Network Open | May 26, 2026 | Volume: 9 | Issue: 5 | Pages: e2614674

10.1001/jamanetworkopen.2026.14674 | PMID 42189543 Get It

This cross-sectional study investigates the association between lipoprotein(a) levels and risk of ventricular arrhythmias among patients with heart failure with reduced ejection fraction receiving implantable cardioverter-defibrillator therapy.
American Radium Society (ARS) Appropriate Use Criteria (AUC) for Low-Dose Radiotherapy for Treatment of Osteoarthritis
Dove, Austin, Koneru, Bobby, Small, William, Nelson, Amanda E., Jeffries, Matlock, Bennion, Phillip, Jones, Craig, Campbell, S., Tendulkar, Rahul, Russo, Suzanne , Lester, Scott, Jethwa, Krishan, Hofstetter, Catherine , Appleton, Tom, Shaffer, Richard, Russo, Suzanne , Dove, Austin P.H. , Koneru, Bobby Nagendra , Small, William, Wright, Jean L. , Jeffries, Matlock Arizona

Mayo Clinic

American Journal of Clinical Oncology | May 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/coc.0000000000001333 | PMID 42184209 Get It

Objectives: To summarize current evidence for radiotherapy in the treatment of OA. The population, intervention, comparator, and outcome questions included: What is the role of LDRT for treatment of OA?; What are risks of LDRT?; and What are the optimal RT techniques for OA? Methods: This multispecialty-led committee includes radiation oncologists, rheumatologists, orthopedic surgeons, and a patient advocate. Using the population, intervention, comparator, outcome, timing and study design (PICOTS) framework, evidence regarding treatment outcomes was assessed using Cochrane and PRISMA methodology. Eligible studies included prospective and retrospective (n≥50) studies published between January 1, 2010, and May 10, 2025, from Embase, Medline, and PubMed databases. Study type and quality were assessed. Well-established RAND-UCLA consensus methodology (modified Delphi) was used to rate the appropriateness of the treatment options. Results: Of the 548 articles identified using the search strategy, 44 were selected for inclusion. Eight additional studies were identified through backward citation searching. Ten well-designed studies accounting for biases, 15 moderately well-designed studies accounting for the most common biases, 18 studies with design limitations, 8 supplemental studies not useful as primary evidence, and 1 meta-analysis were included. Additional studies were included to provide context and were not used to guide recommendations. The results of this analysis demonstrate that LDRT results in an overall treatment response rate of 60% to 90%, with significant clinical benefits including pain reduction, increased joint mobility, and improved quality of life. Conclusions: This systematic review and consensus guidelines for LDRT treatment of OA are based on current evidence. Further high-quality studies are warranted.
Biophysical Diffusion MRI Models Better Identify White Matter Tracts in Edema
Prentiss, Isaac E. , Hakhu, Sasha , VanGilder, Jennapher Lingo , Hareesh, Parvathy , Hooyman, Andrew , Hines, Justin, LaFond, Gabe, Ofori, Edward , Baxter, Leslie C. , Zhou, Yuxiang, Hu, Leland , Schilling, Kurt G., Beeman, Scott C. , Ofori, Edward , Ofori, Edward , Baxter, Leslie C. , Beeman, Scott C , Prentiss, Isaac , Yalim, Jason , LaFond, Gabe, Zhou, Yuxiang , Schilling, Kurt G.

Mayo Clinic

Tomography | May 25, 2026 | Volume: 12 | Issue: 6 | Pages: 78

10.3390/tomography12060078 | PMID 42347133 Get It

Background/Objectives: White matter (WM) tract detection is critical in the presurgical planning of tumor resection. However, standard-of-care imaging techniques including T1-weighted, T2-weighted, and Diffusion Tensor Imaging (DTI) often fail to identify WM tracts within edematous regions. In T1/T2-weighted imaging, edema increases extracellular water and reduces tissue contrast, and in diffusion-weighted imaging, edema elevates isotropic diffusion, reducing sensitivity to anisotropic diffusion along WM tracts. Advanced biophysical diffusion modeling techniques such as Neurite Orientation Dispersion and Density Imaging (NODDI) and the Standard Model (SM) address this limitation by compartmentalizing the diffusion signal into free-water, intra-neurite, and extra-neurite contributions. Here, we test if biophysical multi-compartment models can robustly identify WM tracts and recover tractography streamlines within edematous regions. Methods: In this study, we use multi-shell diffusion-weighted MRI data obtained from patients with meningiomas—a pathology allowing for isolation of the effects of edema without the confounding effects of tumor cell invasion. We compared FA from standard and free-water-corrected DTI, the orientation dispersion index (ODI) from NODDI, and P2 (a scalar descriptor of fiber orientation coherence) from the SM fODF in edematous and unaffected contralateral WM regions. As a proof of concept, we visually evaluated the tractography performance across models. Results: Our results show that (1 − ODI) and P2 values in edema remained close to within-subject contralateral measurements, contrasting with substantial reductions in FA and FW-FA. (1 − ODI) showed a small but statistically significant increase in edema (~8%, p = 0.02), while P2 was unchanged. Conclusions: These results highlight the potential of biophysical diffusion models for preoperative mapping in edema.
Validation of MELD 3.0 in 2 centers from different continents
Duong, Nikki, Huynh, Daniel J. , Kim, W. Ray, Shah, Neil , Biggins, Scott W. , Kwong, Allison, Kwong, Allison J. , Duong, Nikki , Kwong, Allison , Nikzad, Newsha , Shah, Neil

Mayo Clinic

Hepatology Communications | May 22, 2026 | Volume: 10 | Issue: 6 | Pages: No page available

10.1097/hc9.0000000000000958 | PMID 42172502 Get It

Chromosome 5q deletion drives evolution of aneuploidy in myeloid neoplasms with complex karyotype
Creamer, J. Philip , Ray, Suhita , Stewart, Sintra , Saliba, Antoine N. , Wu, Jieya , Huang, Frank Y. , Leppä, Aino‐Maija , Wang, Bofei , Abbas, Hussein A. , Abkowitz, Janis L. , Appelbaum, Jacob S, Becker, Pamela S., Jobanputra, Vaidehi , Fang, Min, Doulatov, Sergei, Saliba, Antoine N. , Saliba, Antoine N , Leppä, Aino-Maija , Wang, Bofei , Abbas, Hussein A , Kaufmann, Scott H , Becker, Pamela S , Swisher, Elizabeth M , Doulatov, Sergei , Saliba, Antoine N , Creamer, John Philip , Gülsüner, Süleyman , Appelbaum, Jacob , Kaufmann, Scott H. , Trumpp, Andreas , Fang, Min, Swisher, Elizabeth M.

Mayo Clinic

Blood Journal | May 21, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/blood.2025031996 | PMID 42166356 Get It

Clonal acquisition of multiple chromosomal abnormalities in hematopoietic stem and progenitor cells (HSPCs) is a hallmark of high-risk acute myeloid leukemias with complex karyotype (AML-CK). AML-CK is associated with TP53 mutations and chromosome 5q deletions (del5q); however, the drivers and clonal trajectories of aneuploid evolution in HSPCs remain unknown. We have developed a patient-derived induced pluripotent stem cell (iPSC) model in which preleukemic HSPCs clonally evolve to distinct, highly aneuploid states following transient mitotic inhibition. By tracking chromosome evolution at single cell resolution, we show that TP53-mutant HSPCs with del5q, but not TP53­ mutation alone, evolved complex chromosomal changes. Clonal evolution was marked by stepwise acquisition of numerical and structural chromosome changes seen in AML-CK patients, with individual abnormalities conferring fitness advantage. iPSC-derived aneuploid HSPCs and primary AML-CK patient samples exhibited a conserved gene expression signature marked by upregulation of PTEN, cohesins, and anti-apoptotic factor BCL2, indicative of a shared aneuploid cell state in HSPCs. Clinical BCL2 inhibitor venetoclax eradicated BCL2-dependent aneuploid clones, with resistant clones undergoing a lineage switch to upregulate alternative BCL2 factors. In summary, we demonstrate that mutant TP53 and del5q drive chromosome evolution marked by stepwise acquisition of individual abnormalities. Moreover, aneuploid HSPCs exhibit a shared gene expression state which confers unique targetable therapeutic vulnerabilities in AML-CK.